Pegcetacoplan-Empaveli market price and purchase channels

Pegcetacoplan (Pegcetacoplan), as a complement C3 targeting drug that has attracted much attention in recent years, has received widespread attention from the global market due to its innovative mechanism and application in a number of rare diseases. Since it is not currently on the market in China and has not been included in the medical insurance system, its price and purchase channels have become one of the most frequently searched questions by patients. According to the data, the market price of Pegtak with the specification of 1080mg/20ml in the United States is approximately more than 4,700 US dollars, which is a typical high-priced rare disease drug. The reason for the high price is related to its R&D investment, cold chain transportation requirements, production difficulty and the overall market size of the rare disease field. Therefore, the price will not fluctuate much in the short term, but there may be slight changes due to the impact of exchange rates.

Since it has not yet been introduced in China, patients who need it mainly obtain it through overseas medical channels. Some international pharmacies, cross-border medical institutions, and commonly used global drug supply services can provide formal ordering channels, but drug purchases must strictly comply with domestic customs regulations and hospital management requirements. The usual process includes English prescriptions issued by doctors, medical record abstracts, drug import applications, etc. Most of them need to be submitted for review in advance. Since drugs belong to the cold chain transportation category, the transportation method is also relatively special, and temperature control must be ensured throughout the process to avoid affecting the efficacy of the drug.

When inquiring about prices or purchase channels, patients should also pay attention to whether there are overseas charitable aid or pharmaceutical company support projects, because some rare disease drugs will provide financial burden reduction plans. Although the coverage is limited, it will be of certain help to eligible patients. In addition, since Pegcetacoplan has not yet entered the Chinese market and the information on relevant purchase channels is complicated, it is recommended that patients confirm the authenticity of prices and channels through reliable medical consultants or professional platforms to avoid losses caused by informal channels.

References: https://empaveli.com/